WO2004075913A1 - タンパク質含有安定化製剤 - Google Patents
タンパク質含有安定化製剤 Download PDFInfo
- Publication number
- WO2004075913A1 WO2004075913A1 PCT/JP2004/002429 JP2004002429W WO2004075913A1 WO 2004075913 A1 WO2004075913 A1 WO 2004075913A1 JP 2004002429 W JP2004002429 W JP 2004002429W WO 2004075913 A1 WO2004075913 A1 WO 2004075913A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- protein
- solution
- poloxamer
- cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 77
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 74
- 239000004094 surface-active agent Substances 0.000 claims abstract description 40
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000004071 biological effect Effects 0.000 claims abstract description 31
- 229920001983 poloxamer Polymers 0.000 claims abstract description 23
- 229960000502 poloxamer Drugs 0.000 claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 12
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 19
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 19
- 239000000199 parathyroid hormone Substances 0.000 claims description 18
- 229960001319 parathyroid hormone Drugs 0.000 claims description 18
- 229920001993 poloxamer 188 Polymers 0.000 claims description 17
- 229940044519 poloxamer 188 Drugs 0.000 claims description 17
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 16
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 235000018102 proteins Nutrition 0.000 description 57
- 239000000243 solution Substances 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 32
- 108010000499 Thromboplastin Proteins 0.000 description 30
- 102000002262 Thromboplastin Human genes 0.000 description 30
- 230000000694 effects Effects 0.000 description 30
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 23
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 23
- 229920000053 polysorbate 80 Polymers 0.000 description 23
- 229940068968 polysorbate 80 Drugs 0.000 description 23
- 239000000427 antigen Substances 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 238000012360 testing method Methods 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 229940068977 polysorbate 20 Drugs 0.000 description 9
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
- 229930195722 L-methionine Natural products 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102000003951 Erythropoietin Human genes 0.000 description 7
- 108090000394 Erythropoietin Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 229940105423 erythropoietin Drugs 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010014173 Factor X Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000208125 Nicotiana Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010054265 Factor VIIa Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- -1 and in particular Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000012812 general test Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 150000002840 non-reducing disaccharides Chemical class 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000006318 protein oxidation Effects 0.000 description 2
- 238000013094 purity test Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PBTPTBMYJPCXRQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O PBTPTBMYJPCXRQ-MGMRMFRLSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- REYLLNRLWCBKCM-YFKPBYRVSA-N (2s)-2-acetamido-4-sulfanylbutanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCS REYLLNRLWCBKCM-YFKPBYRVSA-N 0.000 description 1
- KQJTXYQXRHCWKW-PJSBSAQXSA-N (4s)-4-[[(2s,3s)-2-benzamido-3-methylpentanoyl]amino]-5-[[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid;hydrochloride Chemical compound Cl.N([C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C1=CC=CC=C1 KQJTXYQXRHCWKW-PJSBSAQXSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920002043 Pluronic® L 35 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 108010031969 benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide Proteins 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 150000002232 fructoses Chemical class 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N gallic acid propyl ester Natural products CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 1
- 229950006389 thiodiglycol Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to a stabilized protein-containing stabilized preparation. More specifically, the present invention relates to a stable protein-containing preparation containing pol oxamer as a surfactant.
- proteins having biological activities such as antibodies, enzymes, hormones, and cytokins can be used as pharmaceuticals.
- antibodies such as immunoglobulins, monoclonal antibodies, and humanized antibodies are unstable proteins, and are subjected to filtration stress, concentration stress, and heat stress during purification and dispensing processes, as well as heat and light during storage of stock solutions and drug products. Physical and chemical changes such as aggregation and aggregation are likely to occur due to transport stress.
- antibody-producing cells are cultured in bulk, the antibody-containing solution obtained by purification is stored frozen, and thawed at the stage of formulation. Repeated freezing and thawing can result in the formation of antibody dimers, insoluble microparticles, and insoluble foreign substances, and the degradation of antibodies during long-term storage to produce degraded products, resulting in a decrease in the residual rate of antibodies. It was a problem.
- An object of the present invention is to provide a surfactant capable of retaining protein biological activity by suppressing protein oxidation without adding an antioxidant and suppressing the production of insoluble foreign substances in protein preparations. And to provide a protein-containing stabilized preparation containing the surfactant. Disclosure of the invention
- the present inventors have found that by adding poloxamer as a surfactant, the biological activity of the protein can be maintained without oxidizing the protein without adding an antioxidant.
- the present inventors have discovered that the formation of insoluble foreign substances in a protein-containing preparation can be suppressed, and completed the present invention.
- the present invention provides the following:
- a protein preparation containing poloxamer as a surfactant (1) A protein preparation containing poloxamer as a surfactant.
- FIG. 1 is a graph showing changes over time in biological activity of anti-human tissue factor antibody solution preparations to which various surfactants have been added.
- FIG. 2 is an anion exchange chromatogram of an anti-human tissue factor antibody solution preparation to which poloxamer-188 or polysorbate 80 was added.
- FIG. 3 is a graph showing the effect of adding L-methionine on the reduction of the activity of anti-human tissue factor antibody by polysorbate 80, and a comparison between the effect of the addition and the effect of adding poloxamer.
- FIG. 4 is a mouthmatogram showing the effect of polysorbate 80, polysorbate 20 or poloxamer 188 on the oxidation of granulocyte colony stimulating factor.
- FIG. 5 is a chromatogram showing the effect of polysorbate 80, polysorbate 20 or poloxamer 188 on parathyroid hormone oxidation.
- a protein-containing preparation refers to a preparation containing a protein as an active ingredient, preferably a physiologically active protein, and prepared so as to be administrable to animals such as humans. including.
- Proteins used in the formulations of the present invention include, but are not limited to, antibodies, enzymes, cytokins, and hormones. Specifically, granulocyte colony stimulating factor (G—CS TJP2004 / 002429
- GM-CSF granulocyte-macrophage colony-stimulating factor
- EPO erythropoietin
- hematopoietic factors such as topompovoetin
- cytochromes such as IL-1 and IL-6
- immunoglobulins Monoclonal antibodies, humanized antibodies, tissue plasminogen activator (TPA), perokinase, serum albumin, blood coagulation factor VIII, lebutin, inulin, stem cell growth factor (SCF), etc. It is not limited to.
- TPA tissue plasminogen activator
- perokinase serum albumin
- blood coagulation factor VIII serum albumin
- SCF stem cell growth factor
- SCF stem cell growth factor
- an anti-tissue factor antibody is particularly preferred.
- the protein used in the preparation of the present invention has substantially the same biological activity as a physiologically active protein of a mammal, especially a human, and is derived from a natural source and obtained by a genetic recombination method. Among them, preferred are those obtained by a genetic recombination method. Proteins obtained by the genetic recombination method are those having the same amino acid sequence as the natural protein, or those in which one or more of the amino acid sequences have been deleted, substituted, or added to have the biological activity. Including those that have Furthermore, the biologically active protein includes those chemically modified with PEG or the like.
- a protein having a sugar chain is particularly preferable.
- the origin of the sugar chain is not particularly limited, but a sugar chain added to a mammalian cell is preferable.
- the mammalian cells include, for example, Chinese eight-muster ovary cells (CHO cells), BHK cells, COS cells, cells derived from humans, and the like. Among them, CHO cells are most preferred.
- EPO may be produced by any method, extracted from human urine by various methods, separated and purified, a genetic engineering method (for example, JP-A-61-12288). ), Produced in Chinese Hams Yuichi ovary cells (CHO), BHK cells, COS cells, cells of human origin, etc., and extracted and separated and purified by various methods.
- EPO chemically modified with PEG or the like see International Patent Application Publication No. WO 90/12874.
- EPO without sugar chains is also chemically modified with PEG or the like.
- EPO analogs that have been modified to increase the number of one or more glycosylation sites at the N-linked carbohydrate chain binding site or the 0-linked carbohydrate chain binding site in the amino acid sequence of EP 0 (For example, Japanese Patent Application Laid-Open No. Hei 8-151398, No. 62 3).
- the amount of sugar chains may be increased by increasing the content of sialic acid or the like without changing the number of sugar chain binding sites.
- any G-CSF can be used as long as it is a highly purified G-CSF.
- the G-CSF in the present invention may be produced by any method, such as those obtained by culturing a cell line of human tumor cells and extracting and separating and purifying it from various methods, or E. coli or the like by genetic engineering techniques. Bacteria; yeast; produced by cultured cells derived from animals such as Chinese hams evening ovary (CHO) cells, C17 cells, COS cells, etc., extracted by various methods, and separated and purified. Preferably, it is produced by a gene recombination method using Escherichia coli, yeast or CHO cells. Most preferably, it is produced by genetic recombination using CHO cells. Further, G-CSF chemically modified with PEG or the like is also included (see International Patent Application Publication No. WO 90/12874).
- the antibody is not particularly limited as long as it binds to a desired antigen, and a mouse antibody, a rat antibody, a heron antibody, a shedding antibody, a chimeric antibody, a humanized antibody, a human antibody, or the like may be appropriately used. it can.
- the antibody may be a polyclonal antibody or a monoclonal antibody, but a monoclonal antibody is preferred because a homogeneous antibody can be stably produced.
- Polyclonal and monoclonal antibodies can be prepared by methods well known to those skilled in the art.
- a hybridoma producing a monoclonal antibody can be basically produced using a known technique as follows. That is, a desired antigen or a cell that expresses the desired antigen is used as a sensitizing antigen and immunized according to a normal immunization method, and the obtained immune cells are compared with known parent cells by a normal cell fusion method. It can be prepared by screening and screening for antibody-producing cells (hybridomas) that are monoclonal by a conventional screening method. The production of a hybridoma can be performed according to, for example, the method of Milstein et al. (Ohler. G. and Milstein, C., Methods Enzymol. (1981) 73: 3-46).
- immunization may be performed by binding to a macromolecule having immunogenicity such as albumin.
- antibody genes are cloned from hybridomas and assembled into an appropriate vector.
- the recombinant antibody can be used by introducing it into a host and producing it using a genetic recombination technique (for example, Carl, AK Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES , Clar shed in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990).
- a genetic recombination technique for example, Carl, AK Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES , Clar shed in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990.
- cDNA of the variable region (V region) of the antibody is synthesized from the hybridoma mRNA using reverse transcriptase.
- DNA encoding the V region of the desired antibody is obtained, it is ligated to DNA encoding the desired antibody constant region (C region) and incorporated into the expression vector.
- DNA encoding the V region of the antibody may be incorporated into an expression vector containing the DNA of the antibody C region.
- An expression control region for example, an enhancer or a promoter, is incorporated into an expression vector so as to be expressed under the control of the promoter.
- host cells can be transformed with this expression vector to express the antibody.
- a recombinant antibody artificially modified for the purpose of, for example, reducing the antigenicity to humans such as a chimeric antibody or a humanized antibody
- modified antibodies can be produced using known methods.
- a chimeric antibody is an antibody consisting of a heavy chain and light chain variable region of a non-human mammal, such as a mouse antibody, and a heavy chain and light chain constant region of a human antibody. Is linked to a DNA encoding the constant region of a human antibody, and this is inserted into an expression vector, introduced into a host, and produced.
- a humanized antibody is also called a reshaped human antibody, and converts the complementarity determining region (CDR) of a non-human mammal, such as a mouse antibody, to the complementarity determining region of a human antibody. It has been transplanted, and its general gene recombination technique is also known. Specifically, a DNA sequence designed to link the CDR of a mouse antibody and the framework region (FR) of a human antibody was prepared by constructing a DNA sequence having an overlapping portion at the end. It is synthesized by PCR from individual oligonucleotides.
- the obtained DNA is ligated to DNA encoding the constant region of a human antibody, then incorporated into an expression vector, and introduced into a host to produce the same (European Patent Application Publication No. EP 239400; Published application number W0 96/02576).
- the FRs of human antibodies linked via CDRs Those that form an antigen-binding site having a good region are selected. If necessary, amino acids in the framework region of the variable region of the antibody may be substituted so that the complementarity-determining region of the reshaped human antibody forms an appropriate antigen-binding site (Sato, L et al., Cancer Res. (1993) 53, 851-856).
- human lymphocytes are sensitized in vitro with a desired antigen or cells expressing the desired antigen, and the sensitized lymphocytes are fused with a human myeloma cell, for example, U266, to obtain a desired antigen having an antigen-binding activity.
- Human antibodies can also be obtained (see Japanese Patent Publication No. 1-59878).
- a desired human antibody can be obtained by immunizing a transgenic animal having the entire repertoire of human antibody genes with an antigen (International Patent Application Publication Nos.
- a technique for obtaining a human antibody by panning using a human antibody library is also known.
- a phage that binds to an antigen can be selected by expressing the variable region of a human antibody as a single-chain antibody (scFv) on the surface of the phage by a phage display method.
- scFv single-chain antibody
- a human antibody can be obtained from the sequence by preparing an appropriate expression vector. These methods are already well known and can be referred to TO 92/01047, W0 92/20791, WO 93/06213, WO 93/1 1236, W0 93/19172, W0 95/01438, 0 95/15388. it can.
- an antibody gene When an antibody gene is once isolated and introduced into an appropriate host to produce an antibody, a combination of an appropriate host and an expression vector can be used.
- animal cells When eukaryotic cells are used as hosts, animal cells, plant cells, and fungal cells can be used.
- Animal cells include (1) mammalian cells, such as CH0, COS, myeloma, BHK (baby hams ter kidney), HeLa, Vero, (2) amphibian cells, such as African omega oocytes, or ( 3) Insect cells, for example, sf9, sf21, Tn5, are known.
- cells derived from the genus Nicotiana may be cultured in callus.
- Fungal cells include yeast, such as the genus Saccharomyces, For example, Saccharomyces serevisiae, filamentous fungi, for example, Aspergillus genus, for example, Aspergillus niger are known.
- yeast such as the genus Saccharomyces, For example, Saccharomyces serevisiae
- filamentous fungi for example, Aspergillus genus, for example, Aspergillus niger are known.
- prokaryotic cells there are production systems that use bacterial cells.
- Escherichia coli (E. coli) and Bacillus subtilis are known as bacterial cells.
- An antibody can be obtained by introducing the antibody gene of interest into these cells by transformation and culturing the transformed cells in vitro.
- antibodies contained in the stabilized preparation of the present invention include anti-IL-6 receptor antibody, anti-HM1.24 antigen monoclonal antibody, anti-parathyroid hormone-related peptide antibody (anti-PTHrP antibody), anti-tissue factor antibody and the like. But not limited to this.
- Examples of reshaped humanized antibodies include humanized anti-IL-16 receptor antibody (hPM-1) (see International Patent Application Publication No. WO 92-19759), humanized anti-HM 1.24 antigen Antibodies (see International Patent Application Publication No. WO 98-14580), humanized anti-parathyroid hormone-related peptide antibodies (anti-PTHrP antibodies) (see International Patent Application Publication No. WO 98-13388), etc. Preferred antibodies used in the above.
- the present applicant has also proposed a human Z mouse chimeric antibody comprising a variable region (V region) of a mouse monoclonal antibody against human tissue factor and a constant region (C region) of a human antibody.
- V region variable region
- C region constant region
- a humanized antibody in which the capture determining regions of the chain (L chain) V region and heavy chain (H chain) V region are transplanted to a human antibody was prepared, and these were used for superior DIC and arterial thrombosis.
- a promising drug for the treatment of venous thrombosis (W099 / 51743, WO 01/24626).
- a humanized anti-human tissue factor antibody in combination with humanized H chain version i and humanized L chain version b2 described in W099 / 51743, which is a recombinant produced by CHO cells.
- Type antibody Many anti-human tissue factor antibodies have already been reported (W099 / 51743, WO88 / 07543, WO96 / 40921, WO98 / 40408, WO01 / 70984).
- the tissue factor serving as an antigen is already known (Ito T et al., J. Biocliem. 114, 691-696, (1993)), it can be prepared by a method known to those skilled in the art. .
- These anti-human tissue factor antibodies are also used in the present invention. Preferred antibodies to use.
- the immunoglobulin class of the antibody contained in the preparation of the present invention may be any,
- IgG such as IgG1, IgG2, IgG3 and IgG4 is preferred.
- the antibody-containing solution may be a solution containing any antibody irrespective of whether it is an antibody derived from a living body or a recombinant antibody.
- the antibody obtained by culturing is used.
- the insoluble foreign substance is defined as the Japanese Pharmacopoeia * General test method, Insoluble injectables
- the solution prepared in a container is placed under a white light source at a brightness of about 1000 lux. Insoluble foreign matter that is clear and easily detected when observed with the naked eye.
- the biological activity of an antibody refers to the ability of the antibody to bind to the antigen, and can be determined by a test method for neutralizing the antigen.
- a test method for neutralizing the antigen for example, in the case of a humanized anti-human tissue factor antibody, the biological activity of an antibody stock solution after the accelerated test in which it is stored at 25 ° C for 6 months When the activity is 100, 60% or more, preferably 70% or more, more preferably 80% or more, and most preferably 90% or more.
- the purity test of the antibody preparation can be performed by gel filtration chromatography and anion exchange chromatography described later.
- Poloxamers are non-ionic surfactants and are a series of block copolymers of ethylene oxide and propylene oxide having the general formula: HO (C 2 H 40 ) a (C 3 H 6 0) b (C 2 H 4 0) a H
- Poloxama Poloxama 124, 188, 237, 338, 407 are listed in USP (US Pharmacopoeia), and in the present invention, Poloxama 188 is particularly preferred.
- a in the above formula is 80, b is 27, TJP2004 / 002429
- the average molecular weight is 7680-9510, and the poloxamer-188 described in BP (British Pharmacopoeia) has a of about 75, b of about 30 and an average molecular weight of 8350 in the above formula.
- the EP European Pharmacopoeia
- Pluronic trademark of BASF Corporation of Poloxama
- Poloxama has been used as an emulsifier in fat emulsions for intravenous injection or as a solubilizer to maintain the transparency of elixirs and syrups in pharmaceutical preparations. Not used as an agent.
- the amount of poloxamer added varies depending on the type of poloxamer used and the concentration and type of protein, but in the case of poloxamer 188, it is generally 0.001 to 100 mg / mL, preferably 0.005 to 50 mg ZmL. More preferably, it is 0.01 to 1 Omg / mL.
- the protein-containing preparation of the present invention may contain an amino acid as a stabilizer.
- Amino acids include, but are not limited to, leucine, tryptophan, serine, glutamic acid, arginine, histidine and lysine and salts thereof.
- sugar alcohols such as mannitol and sorbitol
- non-reducing disaccharides such as sucrose and trehalose
- non-reducing trisaccharides such as raffinose
- Oligosaccharides and the like can also be added.
- non-reducing oligosaccharides are preferred.
- non-reducing disaccharides are preferable, and sucrose and trehalose are more preferable.
- the antibody-containing solution preparation of the present invention preferably contains substantially no protein such as human serum albumin or purified gelatin as a stabilizer.
- the pH of the antibody preparation of the present invention is preferably pH 4 to 8, and more preferably p H is 5 to 7.5. However, pH varies depending on the antibody involved, and is not limited thereto.
- polyethylene glycol, dextran, mannitol sorbitol, inositol, glucose, fructoses, and lac! ⁇ Is, xylose, mannose, mal] ⁇ Sucrose, sucrose, trehalose, raffinose and other saccharides can be used.
- the antibody-containing solution preparation of the present invention may further contain a diluent, a solubilizing agent, an excipient, a pH adjuster, a soothing agent, a buffer, a sulfur-containing reducing agent, an antioxidant, and the like, if desired.
- sulfur-containing reducing agent N-acetyl cysteine, N-acetyl homo cysteine, thioctic acid, thiodiglycol, thioethanolamine, thiodalicerol, thiosorbitol, thioglycolic acid and its salt, sodium thiosulfate, Examples thereof include daltathione, and those having a sulfhydryl group such as a thioalkanoic acid having 1 to 7 carbon atoms.
- Antioxidants include erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, ⁇ -tocopherol, tocopherol acetate, L-ascorbic acid and its salts, L-ascorbic acid palmitate, L-ascorbic acid stearate, and sulfurous acid Chelating agents such as sodium hydrogen hydride, sodium sulfite, triamyl gallate, propyl gallate or disodium ethylenediaminetetraacetate (EDTA), sodium pyrophosphate, sodium metaphosphate and the like can be mentioned.
- Chelating agents such as sodium hydrogen hydride, sodium sulfite, triamyl gallate, propyl gallate or disodium ethylenediaminetetraacetate (EDTA), sodium pyrophosphate, sodium metaphosphate and the like can be mentioned.
- inorganic salts such as sodium chloride, potassium chloride, calcium chloride, sodium phosphate, potassium phosphate, and sodium bicarbonate
- organic salts such as sodium citrate, potassium citrate, and sodium acetate. May be included.
- the preparation of the present invention comprises a phosphate buffer (preferably sodium monohydrogen phosphate and sodium dihydrogen phosphate) and / or a citrate buffer (preferably a sodium citrate buffer) and / or Alternatively, a solution preparation is prepared by dissolving in an aqueous buffer known in the field of a solution preparation such as an acetate buffer.
- concentration of the buffer is generally 1 to 500 mM, preferably 5 to 100 m3 [, and more preferably 10 to 50 mM.
- the antibody-containing solution preparation of the present invention is usually administered by parenteral administration, for example, by injection (subcutaneous injection, Intravenous, intramuscular, intraperitoneal injection, etc.), transdermal, transmucosal, nasal, pulmonary, etc., but oral administration is also possible.
- parenteral administration for example, by injection (subcutaneous injection, Intravenous, intramuscular, intraperitoneal injection, etc.), transdermal, transmucosal, nasal, pulmonary, etc., but oral administration is also possible.
- the protein-containing preparation of the present invention may be a lyophilized preparation or a solution preparation, and a solution preparation is preferred.
- Solution formulations can be supplied in defined volume containers, such as vials, ampoules, and syringes, usually sealed and sterile, made of plastic or glass, and in large volume containers such as bottles. Prefilled syringes are preferred from the viewpoint of convenience of use.
- the amount of the antibody contained in the preparation of the present invention can be determined according to the type of the disease to be treated, the severity of the disease, the age of the patient, etc., but in general, 0.1 to 20 OragXm1, preferably Ms.:! 11 2 O m gZm 1.
- the solution formulation of the present invention can maintain a high biological activity of the antibody formulation without adding an antioxidant, by adding poloxamer as a surfactant, as shown in Examples described later. It was also shown that the formation of insoluble foreign matter was suppressed.
- the present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited thereto. Various changes and modifications can be made by those skilled in the art based on the description of the present invention, and these changes and modifications are also included in the present invention.
- an anti-human tissue factor antibody a humanized anti-human tissue factor antibody obtained by combining humanized H chain version i and humanized L chain version b2 described in W099 / 51743 was used.
- the anti-human tissue factor antibody used in this example is a recombinant antibody produced by CHO cells, and is an IgG 4 class antibody.
- G-CSF Granulocyte colony stimulating factor
- Granulocyte colony stimulating factor was produced by genetic engineering techniques using Chinese hams evening ovary (CHO) cells by genetic recombination, extracted, separated and purified.
- Parathyroid hormone (PTH) Parathyroid hormone having 1 to 84 residues was produced by the method described in W9101415. Test method
- Tissue factor is a blood coagulation factor VII receptor expressed on the cell surface and has been positioned as a substantial initiator of the blood coagulation reaction. Tissue factor activates blood coagulation factors IX and X through complex formation with blood coagulation factor VII. Therefore, the biological activity of the humanized anti-human tissue factor antibody can be measured using a blood coagulation factor Vila solution and a blood coagulation factor X solution by the method described below.
- AB Assay Buffer: TBS (pH 7.6) containing 5 mmol / L CaCl 2 and 0.1% BSA.
- Factor VIIa & Thromborel S mixed solution Factor Vila was diluted with A.B. to 0.1 PEU / mL and Thromborel S to 0.42 mg / mL.
- Factor X solution Factor X was diluted to 0.25 PEU / mL with A.B.
- Test team chromogenic substrate 8-2222 mixed solution 1.5 11 ⁇ / 11 ⁇ chromogenic substrate S-2222 solution 1 was mixed with water 1 and polyprene aqueous solution 2 at a ratio.
- the anti-human tissue factor antibody stock solution (standard solution) and the sample solution diluted with the Factor X solution were dispensed at 40 / well to the above plate, and allowed to stand at room temperature for 30 minutes.
- test team coloring substrate S-2222 was dispensed at 50 / well to the plate and allowed to stand at room temperature for 30 minutes. 5. The absorbance at 405 nm to 655 nm was measured.
- BSA Bovine Serum Albumin
- the test was performed under the following conditions.
- the formulation containing polysorbate 80 significantly reduced the biological activity of the anti-human tissue factor antibody, while the formulation containing poloxamer 188 retained the same activity as the formulation without the surfactant. A decrease in activity was also observed when polysorbate 20, a surfactant that had been used as an injection, was added.
- Example 2 Effect of surfactant on biological activity and purity
- Fig. 3 shows the obtained results.
- the decrease in activity due to polysorbate 80 could be suppressed by the addition of L-methionine.
- Poloxama-188-supplemented samples exhibited the same or better biological activity than the polysorbate-80 and L-methionine-supplemented samples.
- Example 4 Effect of surfactant on insoluble foreign matter
- the effect of the surfactant on the granulocyte colony stimulating factor solution preparation was examined.
- a sample (PH6.5) containing 0.25 mg / mL colony stimulating factor in a phosphate buffer solution was used as a surfactant for polysorbate 80 (manufactured by Company A), polysorbate 20 (manufactured by Company A), After an accelerated test in which Poloxama-188 (manufactured by Company B) was added to 0.05% each and stored at 25 ° C for 5 weeks, the amount of oxidized form of granulocyte colony-stimulating factor was determined by reverse phase chromatography (RPC). It was measured.
- RPC reverse phase chromatography
- the test was performed under the following conditions.
- parathyroid hormone stimulating factor solution formulation The effect of the surfactant on the parathyroid hormone stimulating factor solution formulation was examined.
- 0.25 mg ZmL of parathyroid hormone in a citrate buffer (pH 5.0) was used as a surfactant for polysorbate 80 (manufactured by Company A) and polysorbate 20 (manufactured by Company A).
- poloxamer-188 manufactured by Company B were added at 0.05% each, and after an accelerated test of storage at 40 ° C for 2 weeks, the amount of oxidized parathyroid hormone was measured by reverse phase chromatography (RPC). .
- the test was performed under the following conditions.
- poloxamer 188 was more effective at suppressing the oxidation of the protein solution preparation than polysorbates.
- the stabilized preparation containing protein of the present invention does not decrease in biological activity even after long-term storage, and does not generate insoluble foreign substances.
- it is a stable formulation in which the rate of protein oxidant formation is effectively suppressed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/547,366 US8765124B2 (en) | 2003-02-28 | 2004-02-27 | Stabilized preparation containing protein |
KR1020057015821A KR101235507B1 (ko) | 2003-02-28 | 2004-02-27 | 단백질을 함유하는 안정화 제제 |
CA2517310A CA2517310C (en) | 2003-02-28 | 2004-02-27 | Stabilized protein-containing formulations comprising a poloxamer |
EP04715529.6A EP1598074B1 (en) | 2003-02-28 | 2004-02-27 | Stabilized protein-containing formulations |
AU2004216298A AU2004216298B2 (en) | 2003-02-28 | 2004-02-27 | Stabilized protein-containing formulations |
JP2005502969A JP4607010B2 (ja) | 2003-02-28 | 2004-02-27 | タンパク質含有安定化製剤 |
HK06106720A HK1084340A1 (en) | 2003-02-28 | 2006-06-12 | Stabilized preparation containing protein |
US12/415,400 US9968677B2 (en) | 2003-02-28 | 2009-03-31 | Stabilized protein-containing formulations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-053379 | 2003-02-28 | ||
JP2003053379 | 2003-02-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/547,366 A-371-Of-International US8765124B2 (en) | 2003-02-28 | 2004-02-27 | Stabilized preparation containing protein |
US12/415,400 Division US9968677B2 (en) | 2003-02-28 | 2009-03-31 | Stabilized protein-containing formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004075913A1 true WO2004075913A1 (ja) | 2004-09-10 |
Family
ID=32923431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/002429 WO2004075913A1 (ja) | 2003-02-28 | 2004-02-27 | タンパク質含有安定化製剤 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8765124B2 (ja) |
EP (1) | EP1598074B1 (ja) |
JP (2) | JP4607010B2 (ja) |
KR (1) | KR101235507B1 (ja) |
CN (1) | CN100353997C (ja) |
AU (1) | AU2004216298B2 (ja) |
CA (1) | CA2517310C (ja) |
HK (1) | HK1084340A1 (ja) |
WO (1) | WO2004075913A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007108505A1 (ja) | 2006-03-22 | 2007-09-27 | Chugai Seiyaku Kabushiki Kaisha | エリスロポエチン溶液製剤 |
JP2009507838A (ja) * | 2005-09-12 | 2009-02-26 | ノビミューン エスアー | 抗cd3抗体製剤 |
JP2009521482A (ja) * | 2005-12-21 | 2009-06-04 | ワイス | 低粘度のタンパク質製剤およびその用途 |
JP2014522807A (ja) * | 2011-06-17 | 2014-09-08 | アレス トレーディング ソシエテ アノニム | Fgf−18の凍結乾燥製剤 |
RU2565809C2 (ru) * | 2009-03-19 | 2015-10-20 | Чугаи Сейяку Кабусики Кайся | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами |
JP2016193911A (ja) * | 2010-03-01 | 2016-11-17 | サイトダイン インコーポレイテッドCytoDyn, Inc. | 濃縮されたタンパク質製剤およびその使用 |
JP2021088606A (ja) * | 2017-09-22 | 2021-06-10 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
KR20230017222A (ko) | 2020-05-29 | 2023-02-03 | 추가이 세이야쿠 가부시키가이샤 | 항체 함유 제제 |
WO2023100975A1 (ja) * | 2021-12-01 | 2023-06-08 | 中外製薬株式会社 | 抗体含有製剤の調製方法 |
US12122850B2 (en) | 2023-03-14 | 2024-10-22 | LamKap Bio gamma AG | Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
EP2044934A1 (en) | 2007-10-01 | 2009-04-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof |
EP2052736A1 (en) * | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
ES2382443T3 (es) * | 2008-09-03 | 2012-06-08 | Octapharma Ag | Composiciones estabilizadas para factor VIII producido de manera recombinante |
SG10201401995UA (en) * | 2009-05-04 | 2014-08-28 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
CA2815689C (en) | 2010-11-11 | 2016-11-22 | Abbvie Biotechnology Ltd. | Improved high concentration anti-tnf.alpha. antibody liquid formulations |
TWI723339B (zh) | 2011-05-02 | 2021-04-01 | 美商千禧製藥公司 | 抗-α4β7抗體之調配物 |
US9603909B2 (en) | 2012-05-29 | 2017-03-28 | Intron Biotechnology, Inc. | Composition capable of improving stability of bacteriophage lysin proteins |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
CN104761645A (zh) * | 2015-04-30 | 2015-07-08 | 山东禹王制药有限公司 | α干扰素融合蛋白制剂及应用 |
CN104906053B (zh) * | 2015-06-12 | 2018-01-16 | 北京四环生物制药有限公司 | 注射用重组人粒细胞刺激因子冻干粉针剂 |
KR101699244B1 (ko) * | 2015-08-25 | 2017-01-24 | 주식회사 인트론바이오테크놀로지 | 박테리오파지 리신 단백질들의 안정성을 개선할 수 있는 조성물 |
WO2017115773A1 (ja) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Fc領域含有ポリペプチドの精製を効率化するための方法 |
US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
WO2020002650A1 (en) * | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
CN112516291B (zh) * | 2019-09-17 | 2023-07-14 | 通化安睿特生物制药股份有限公司 | 含人白蛋白的制剂及其制备方法 |
GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
CN114544926A (zh) * | 2021-12-02 | 2022-05-27 | 浙江鑫科医疗科技有限公司 | 一种血清蛋白稳定剂 |
WO2024022414A1 (zh) * | 2022-07-29 | 2024-02-01 | 舒泰神(北京)生物制药股份有限公司 | 一种高浓度单克隆抗体制剂及其应用 |
CN118121744A (zh) * | 2023-12-25 | 2024-06-04 | 深圳柏垠生物科技有限公司 | 一种高稳定性的贻贝粘蛋白组合物、其用途、及其制备方法 |
CN118652320A (zh) * | 2024-08-16 | 2024-09-17 | 通化安睿特生物制药股份有限公司 | 一种速溶重组人白蛋白冻干的制备方法及其应用 |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63146826A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
JPH01168624A (ja) * | 1987-11-27 | 1989-07-04 | Akzo Nv | 抗体の安定化 |
WO1994003157A1 (en) * | 1992-07-28 | 1994-02-17 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions for transmucosal delivery of peptides |
JPH06172199A (ja) * | 1992-12-07 | 1994-06-21 | Tsumura & Co | ペプチド類経鼻投与用組成物 |
JPH07165567A (ja) * | 1993-10-05 | 1995-06-27 | L'oreal Sa | レチノールを主成分とする化粧または薬理組成物 |
JPH0925242A (ja) * | 1995-05-11 | 1997-01-28 | Sanofi Sa | 尿酸オキシダーゼ含有の安定した液体組成物およびその調製用凍結乾燥組成物 |
JPH09194348A (ja) * | 1996-01-10 | 1997-07-29 | Lg Chem Ltd | 持続性動物成長ホルモン製剤およびその製造方法 |
JPH09301887A (ja) * | 1996-02-01 | 1997-11-25 | Chugai Pharmaceut Co Ltd | 血小板減少症の予防剤および治療剤 |
WO1999016421A1 (en) * | 1997-09-29 | 1999-04-08 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
WO1999017743A1 (en) * | 1997-10-07 | 1999-04-15 | Fuisz Technologies Ltd. | Dosage forms having improved release properties |
WO1999044631A1 (en) * | 1998-03-07 | 1999-09-10 | Daewoong Pharmaceutical Co., Ltd. | Topical composition containing human epidermal growth factor |
WO1999045953A1 (fr) * | 1998-03-09 | 1999-09-16 | Welfide Corporation | Compositions contenant un cofacteur ii de l'heparine et techniques de stabilisation |
WO1999051743A1 (fr) * | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises |
JPH11515002A (ja) * | 1995-10-17 | 1999-12-21 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 副甲状腺ホルモンを含む安定な医薬投与形態 |
WO1999066044A1 (en) * | 1998-06-19 | 1999-12-23 | Xoma Technology Ltd. | Bactericidal/permeability-increasing protein (bpi) deletion analogs |
WO2000010526A2 (en) * | 1998-08-21 | 2000-03-02 | Novartis Ag | New oral formulation for 5-ht4 agonists or antagonists |
WO2000023098A1 (en) * | 1998-10-16 | 2000-04-27 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
WO2000023101A1 (en) * | 1998-10-22 | 2000-04-27 | Eli Lilly And Company | Methods for treating sepsis |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
WO2000071149A2 (en) * | 1999-05-24 | 2000-11-30 | Xoma (Us) Llc | Therapeutic uses of bpi protein products in humans with otitis media with effusion |
JP2001501974A (ja) * | 1997-03-24 | 2001-02-13 | グラクソ、グループ、リミテッド | 医薬組成物 |
JP2001503781A (ja) * | 1996-11-19 | 2001-03-21 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤 |
WO2001024626A1 (fr) * | 1999-10-01 | 2001-04-12 | Chugai Seiyaku Kabushiki Kaisha | Prevention et traitement de maladies associees a la coagulation sanguine |
WO2001058474A2 (en) * | 2000-02-10 | 2001-08-16 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active agent |
WO2002002136A1 (fr) * | 2000-06-30 | 2002-01-10 | Suntory Limited | Constituants medicinaux comportant de l'hormone parathyroidienne humaine et compositions medicinales pour l'administration nasale contenant lesdits constituants |
WO2002009667A2 (de) * | 2000-07-28 | 2002-02-07 | Pharmasol Gmbh | Dispersionen zur formulierung wenig oder schwer löslicher wirkstoffe |
WO2002017932A1 (fr) * | 2000-08-30 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations d'oct |
JP2002371009A (ja) * | 2001-04-10 | 2002-12-26 | Kyowa Hakko Kogyo Co Ltd | 顆粒球コロニー刺激因子の薬理効果の持続時間延長方法 |
JP2003342193A (ja) * | 2002-05-30 | 2003-12-03 | Otsuka Pharmaceut Co Ltd | 注射用製剤 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
GR871067B (en) | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
JPS63146828A (ja) | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
DK174044B1 (da) | 1986-12-23 | 2002-05-06 | Kyowa Hakko Kogyo Kk | Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid....... |
WO1995003783A1 (en) * | 1990-03-06 | 1995-02-09 | Houston Biotechnology Incorporated | Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
DE69428521T2 (de) * | 1993-02-02 | 2002-05-23 | Xoma Technology Ltd | Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid |
JP3862295B2 (ja) | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | 抗肥満剤 |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
JPH09174348A (ja) | 1995-12-22 | 1997-07-08 | Nitto Seiko Co Ltd | ねじ締めユニット |
US6342477B1 (en) | 1996-02-01 | 2002-01-29 | Chugai Seiyaku Kabushiki Kaisha | Remedies for thrombocytopenia |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
JPH1168624A (ja) * | 1997-08-08 | 1999-03-09 | Sony Corp | 等化回路 |
DK0917879T3 (da) * | 1997-11-22 | 2002-11-04 | Roche Diagnostics Gmbh | Forbedret fremgangsmåde til stabilisering af proteiner |
AU749815B2 (en) * | 1998-03-06 | 2002-07-04 | Chugai Seiyaku Kabushiki Kaisha | Protein-free preparations |
WO2001024826A2 (en) | 1999-10-06 | 2001-04-12 | The Brigham And Women's Hospital, Inc. | Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens |
NL1013456C2 (nl) * | 1999-11-02 | 2001-05-03 | Dsm Nv | Kristallijn melamine en de toepassing in aminoformaldehydeharsen. |
AU2001250814B2 (en) | 2000-03-16 | 2007-02-15 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
DE10195959T1 (de) * | 2000-03-22 | 2003-10-30 | Rotary Drilling Technology Llc | Bohrspitzenstabilisator |
CA2466034C (en) * | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
AU2003211991B2 (en) * | 2002-02-14 | 2008-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution formulations |
JP4585736B2 (ja) * | 2002-04-24 | 2010-11-24 | 株式会社日立製作所 | サーバ装置 |
-
2004
- 2004-02-27 WO PCT/JP2004/002429 patent/WO2004075913A1/ja active Application Filing
- 2004-02-27 KR KR1020057015821A patent/KR101235507B1/ko active IP Right Grant
- 2004-02-27 CA CA2517310A patent/CA2517310C/en not_active Expired - Lifetime
- 2004-02-27 EP EP04715529.6A patent/EP1598074B1/en not_active Expired - Lifetime
- 2004-02-27 US US10/547,366 patent/US8765124B2/en not_active Expired - Lifetime
- 2004-02-27 CN CNB2004800030798A patent/CN100353997C/zh not_active Expired - Lifetime
- 2004-02-27 JP JP2005502969A patent/JP4607010B2/ja not_active Expired - Lifetime
- 2004-02-27 AU AU2004216298A patent/AU2004216298B2/en not_active Expired
-
2006
- 2006-06-12 HK HK06106720A patent/HK1084340A1/xx not_active IP Right Cessation
-
2009
- 2009-03-31 US US12/415,400 patent/US9968677B2/en not_active Expired - Lifetime
-
2010
- 2010-07-05 JP JP2010153113A patent/JP5377431B2/ja not_active Expired - Lifetime
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63146826A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
JPH01168624A (ja) * | 1987-11-27 | 1989-07-04 | Akzo Nv | 抗体の安定化 |
WO1994003157A1 (en) * | 1992-07-28 | 1994-02-17 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions for transmucosal delivery of peptides |
JPH06172199A (ja) * | 1992-12-07 | 1994-06-21 | Tsumura & Co | ペプチド類経鼻投与用組成物 |
JPH07165567A (ja) * | 1993-10-05 | 1995-06-27 | L'oreal Sa | レチノールを主成分とする化粧または薬理組成物 |
JPH0925242A (ja) * | 1995-05-11 | 1997-01-28 | Sanofi Sa | 尿酸オキシダーゼ含有の安定した液体組成物およびその調製用凍結乾燥組成物 |
JPH11515002A (ja) * | 1995-10-17 | 1999-12-21 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 副甲状腺ホルモンを含む安定な医薬投与形態 |
JPH09194348A (ja) * | 1996-01-10 | 1997-07-29 | Lg Chem Ltd | 持続性動物成長ホルモン製剤およびその製造方法 |
JPH09301887A (ja) * | 1996-02-01 | 1997-11-25 | Chugai Pharmaceut Co Ltd | 血小板減少症の予防剤および治療剤 |
JP2001503781A (ja) * | 1996-11-19 | 2001-03-21 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤 |
JP2001501974A (ja) * | 1997-03-24 | 2001-02-13 | グラクソ、グループ、リミテッド | 医薬組成物 |
WO1999016421A1 (en) * | 1997-09-29 | 1999-04-08 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
WO1999017743A1 (en) * | 1997-10-07 | 1999-04-15 | Fuisz Technologies Ltd. | Dosage forms having improved release properties |
WO1999044631A1 (en) * | 1998-03-07 | 1999-09-10 | Daewoong Pharmaceutical Co., Ltd. | Topical composition containing human epidermal growth factor |
WO1999045953A1 (fr) * | 1998-03-09 | 1999-09-16 | Welfide Corporation | Compositions contenant un cofacteur ii de l'heparine et techniques de stabilisation |
WO1999051743A1 (fr) * | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises |
WO1999066044A1 (en) * | 1998-06-19 | 1999-12-23 | Xoma Technology Ltd. | Bactericidal/permeability-increasing protein (bpi) deletion analogs |
WO2000010526A2 (en) * | 1998-08-21 | 2000-03-02 | Novartis Ag | New oral formulation for 5-ht4 agonists or antagonists |
WO2000023098A1 (en) * | 1998-10-16 | 2000-04-27 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
WO2000023101A1 (en) * | 1998-10-22 | 2000-04-27 | Eli Lilly And Company | Methods for treating sepsis |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
WO2000071149A2 (en) * | 1999-05-24 | 2000-11-30 | Xoma (Us) Llc | Therapeutic uses of bpi protein products in humans with otitis media with effusion |
WO2001024626A1 (fr) * | 1999-10-01 | 2001-04-12 | Chugai Seiyaku Kabushiki Kaisha | Prevention et traitement de maladies associees a la coagulation sanguine |
WO2001058474A2 (en) * | 2000-02-10 | 2001-08-16 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active agent |
WO2002002136A1 (fr) * | 2000-06-30 | 2002-01-10 | Suntory Limited | Constituants medicinaux comportant de l'hormone parathyroidienne humaine et compositions medicinales pour l'administration nasale contenant lesdits constituants |
WO2002009667A2 (de) * | 2000-07-28 | 2002-02-07 | Pharmasol Gmbh | Dispersionen zur formulierung wenig oder schwer löslicher wirkstoffe |
WO2002017932A1 (fr) * | 2000-08-30 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations d'oct |
JP2002371009A (ja) * | 2001-04-10 | 2002-12-26 | Kyowa Hakko Kogyo Co Ltd | 顆粒球コロニー刺激因子の薬理効果の持続時間延長方法 |
JP2003342193A (ja) * | 2002-05-30 | 2003-12-03 | Otsuka Pharmaceut Co Ltd | 注射用製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1598074A4 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507838A (ja) * | 2005-09-12 | 2009-02-26 | ノビミューン エスアー | 抗cd3抗体製剤 |
JP2009521482A (ja) * | 2005-12-21 | 2009-06-04 | ワイス | 低粘度のタンパク質製剤およびその用途 |
US8546329B2 (en) | 2006-03-22 | 2013-10-01 | Chugai Seiyaku Kabushiki Kaisha | Erythropoietin solution preparation |
WO2007108505A1 (ja) | 2006-03-22 | 2007-09-27 | Chugai Seiyaku Kabushiki Kaisha | エリスロポエチン溶液製剤 |
RU2565809C2 (ru) * | 2009-03-19 | 2015-10-20 | Чугаи Сейяку Кабусики Кайся | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами |
US9956165B2 (en) | 2010-03-01 | 2018-05-01 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
US11571383B2 (en) | 2010-03-01 | 2023-02-07 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
JP2016193911A (ja) * | 2010-03-01 | 2016-11-17 | サイトダイン インコーポレイテッドCytoDyn, Inc. | 濃縮されたタンパク質製剤およびその使用 |
US9326944B2 (en) | 2011-06-17 | 2016-05-03 | Ares Trading S.A. | Freeze-dried formulations of FGF-18 |
JP2014522807A (ja) * | 2011-06-17 | 2014-09-08 | アレス トレーディング ソシエテ アノニム | Fgf−18の凍結乾燥製剤 |
JP2021088606A (ja) * | 2017-09-22 | 2021-06-10 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
KR20230017222A (ko) | 2020-05-29 | 2023-02-03 | 추가이 세이야쿠 가부시키가이샤 | 항체 함유 제제 |
WO2023100975A1 (ja) * | 2021-12-01 | 2023-06-08 | 中外製薬株式会社 | 抗体含有製剤の調製方法 |
US12122850B2 (en) | 2023-03-14 | 2024-10-22 | LamKap Bio gamma AG | Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells |
Also Published As
Publication number | Publication date |
---|---|
CN1744912A (zh) | 2006-03-08 |
US8765124B2 (en) | 2014-07-01 |
EP1598074A1 (en) | 2005-11-23 |
KR20050113199A (ko) | 2005-12-01 |
US20090264629A1 (en) | 2009-10-22 |
JP5377431B2 (ja) | 2013-12-25 |
JPWO2004075913A1 (ja) | 2006-06-01 |
CA2517310C (en) | 2015-11-24 |
JP4607010B2 (ja) | 2011-01-05 |
JP2010215664A (ja) | 2010-09-30 |
US9968677B2 (en) | 2018-05-15 |
EP1598074A4 (en) | 2011-10-26 |
AU2004216298A1 (en) | 2004-09-10 |
CN100353997C (zh) | 2007-12-12 |
HK1084340A1 (en) | 2006-07-28 |
EP1598074B1 (en) | 2019-01-02 |
CA2517310A1 (en) | 2004-09-10 |
US20060159653A1 (en) | 2006-07-20 |
KR101235507B1 (ko) | 2013-02-20 |
AU2004216298B2 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5377431B2 (ja) | タンパク質含有安定化製剤 | |
CA2474943C (en) | Sugar stabilized antibody-containing solution formulations | |
EP1977763A1 (en) | Antibody-containing stabilizing preparation | |
EP1428537B1 (en) | Stabilized preparations containing antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004216298 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004216298 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048030798 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004715529 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005502969 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057015821 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2517310 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006159653 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10547366 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004715529 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057015821 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10547366 Country of ref document: US |